BiotechTube
InVivo Biosystems

InVivo Biosystems

Eugene, United States· Est.
invivobiosystems.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

InVivo Biosystems provides an integrated technology and services platform designed to compress preclinical discovery timelines. Its RapidGen™ Platform utilizes high-throughput, in vivo genetic models and Adaptive AI to deliver human-relevant insights on efficacy, safety, and mechanism of action in weeks to months. The company serves over 400 biotech and academic clients, has delivered 600+ studies, and holds a foundational IP portfolio of 10+ patents. It operates as a private, revenue-generating CRO/platform company, enabling external partners' pipelines rather than developing its own therapeutics.

Neurodegenerative DiseasesOncologyOcular DiseaseMetabolic DisordersMonogenic/Rare Diseases

Technology Platform

RapidGen™ Platform: An AI-powered, integrated platform combining high-throughput genetic engineering in whole-organism models (zebrafish, C. elegans), multiplexed in vivo phenotyping (behavior, morphology, transcriptomics, proteomics), and Adaptive AI-driven data analysis to accelerate target validation and therapeutic discovery.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The massive and growing need for faster, more predictive preclinical models in drug discovery presents a significant opportunity.
The company can capitalize on trends toward AI-enabled biology and the outsourcing of complex R&D by expanding its platform capabilities, forming deep strategic partnerships with large pharma, and potentially leveraging its aggregated data as a proprietary asset.

Risk Factors

Revenue is dependent on the cyclical R&D spending of biotech clients.
Intense competition from both traditional CROs and new AI-discovery startups requires constant innovation.
Scientific risk remains regarding the translational fidelity of its model organisms to human outcomes, which is core to its value proposition.

Competitive Landscape

InVivo competes with traditional preclinical CROs (e.g., Charles River, Envigo) offering rodent models, specialized zebrafish CROs, and a growing cohort of AI-for-drug-discovery companies (e.g., Recursion, Exscientia) that often use cell-based assays. Its differentiation lies in combining high-throughput, whole-organism in vivo data with dedicated AI analysis, a niche currently with few direct peers.

More companies in Digital Health & Biotech SaaS →More companies in United States →